Overview

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Status:
RECRUITING

Trial end date:
2033-03-31

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and/or safety of multiple therapies in patients with early-stage resectable NSCLC. Cohort B1 is a phase II cohort that will evaluate the safety, and efficacy of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection. Cohort B2 is a phase II cohort that will evaluate the efficacy and safety of perioperative alectinib in combination with chemotherapy in the neoadjuvant setting.

Phase:

PHASE3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

alectinib
Carboplatin
Cisplatin
Pemetrexed